CN107903248B - N- replaces the Isatine derivatives and application in preparation of anti-tumor drugs of isatin heterozygosis quinazoline compounds synthesis - Google Patents
N- replaces the Isatine derivatives and application in preparation of anti-tumor drugs of isatin heterozygosis quinazoline compounds synthesis Download PDFInfo
- Publication number
- CN107903248B CN107903248B CN201711118862.4A CN201711118862A CN107903248B CN 107903248 B CN107903248 B CN 107903248B CN 201711118862 A CN201711118862 A CN 201711118862A CN 107903248 B CN107903248 B CN 107903248B
- Authority
- CN
- China
- Prior art keywords
- base
- diethyllaminoethyl
- ketone
- quinoline
- quinazoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention discloses Isatine derivatives and application in preparation of anti-tumor drugs that a kind of N- replaces the synthesis of isatin heterozygosis quinazoline compounds, the structural formula of the derivative is
Description
Technical field
The invention belongs to the synthesis technical fields of anti-tumor drug, and in particular to a kind of novel N- replaces isatin hydrazone heterozygosis
4- fragrant amino -6- (5- formylfuran -2- base) quinazoline synthesis Isatine derivatives and they preparing anti-tumor drug
In purposes.
Background technique
Cancer is also known as malignant tumour, is one of the disease for seriously endangering human health.Traditional treatment side of malignant tumour
Method has: radiotherapy, operative treatment, chemotherapy, but itself has some limitations.Anticancer drug is largely thin
Born of the same parents' poison class drug, this kind of drug also have great toxic side effect while killing cancer cell, to normal human tissue cell.
Therefore, the high anticancer drug of research and development synthesis of selective has become the hot spot of research field.In recent years, people, which have begun to focus on, is directed to
Key gene, regulatory molecule and specific cells receptor are the research of the drug of therapy target.
Studies have shown that tyrosine kinase plays an important role in cell growth, proliferation, atomization, when it is excessively living
When change, cell growth control is out of hand, and death is obstructed, and is in vegetative state always, finally results in the generation of malignant tumour.Cause
This, inhibits tyrosine kinase activity, and the signal transduction path for blocking it to activate becomes one of the new way for the treatment of tumour.
EGF-R ELISA (EGFR) signal path has multiple biological action, in human tumor cell often
It expresses and out of hand, it is closely related with the formation of tumour.Therefore, therapy field of the EGFR tyrosine kinase inhibitor in tumour
It has been to be concerned by more and more people.EGFR tyrosine kinase inhibitor can interfere or block the expression approach of receptor protein, have
The phosphorylation of the control downstream signal of effect, to inhibit the process of tumor cell proliferation, division, and then accelerates tumour cell to wither
It dies, achievees the purpose that treat tumour.
Until up to now, it has been found that EGFR tyrosine kinase inhibitor have: indoles, flavones, osajin, quinoline
The compounds such as oxazolines, aryl urea and miazines.Wherein, active higher, the preferable small molecule tyrosine-kinase of selectivity
Enzyme inhibitor is 4- fragrant amino quinazoline compounds, the anti-tumor drug listed such as: it is Lapatinib (Lapatinib), lucky
It is non-to replace Buddhist nun (Gefitinib, Iressa) and Vande Thani (Vandetanib) etc..These drugs play in the treatment of tumour
Good effect, but certain side effect and drug resistance can be generated after being used for a long time, the effect for the treatment of tumour is reduced, and after being
Phase treatment affects.Thus, it is found that and synthesizing the small anti-tumor drug low with drug resistance of toxic side effect as in current weight
Weight.Lapatinib is 4- fragrant amino quinazoline compounds, the small molecule junket ammonia as a kind of novel reversible double target spots
Acid kinase inhibitor has in terms of the treatment Several Kinds of Malignancy especially breast cancer in advanced stage and has a better effect.Isatin is one
A critically important medicine intermediate and raw material, isatin and its derivative have a variety of physiological activity.C-3 replaces Isatine derivatives
Physiological activity includes anticancer, antiviral, anticonvulsion etc..When C-3 is hydrazone or imines replaces, tyrosine-kinase enzyme activity can be inhibited
Property.The heterozygosis of pharmacophoric group is a kind of method of effective, common discovery novel drugs, two or more bioactivity
The heterozygosis of segment has complementary pharmacodynamic feature or different mechanism of action, typically exhibits the effect of collaboration.
Summary of the invention
Technical problem to be solved by the present invention lies in provide a new class of N- with anti-tumor activity to replace isatin hydrazone
It is prepared by the Isatine derivatives and these compounds of heterozygosis 4- fragrant amino -6- (5- formylfuran -2- base) quinazoline synthesis
Purposes in anti-tumor drug.
The structural formula for solving Isatine derivatives used by above-mentioned technical problem is as follows:
X represents hydrogen, fluorine, chlorine, bromine, any one in iodine in formula, Ar represent the chloro- 4- fluorophenyl of 3- ethynyl phenyl, 3-,
Any one in the chloro- 4- of 3- (3- fluorine benzyloxy) phenyl, 4- (E)-acrylic phenyl.
Any one in the above-mentioned preferred following compounds A~I of Isatine derivatives:
A:(E) -1- (2- (diethyllaminoethyl) -3- (((E)-(5- (4- (3- 3-ethynylphenylamino) quinazoline -6- base) furan
Mutter -2- base) methylene) hydrazono-) indole-2-ketone
B:(E) -1- (2- (diethyllaminoethyl) -3- (((E)-(5- (4- (3- 3-ethynylphenylamino) quinazoline -6- base) furan
Mutter -2- base) methylene) hydrazono-) -5- fluoro indole quinoline -2- ketone
C:(E) -1- (2- (diethyllaminoethyl) -3- (((E)-(5- (4- (3- 3-ethynylphenylamino) quinazoline -6- base) furan
Mutter -2- base) methylene) hydrazono-) -5--bromo indole quinoline -2- ketone
D:(E) -1- (2- (diethyllaminoethyl) -3- (((E)-(5- (4- (the chloro- 4- fluoroanilino of 3-) quinazoline -6- base)
Furans -2- base) methylene) hydrazono-) indole-2-ketone
E:(E) -1- (2- (diethyllaminoethyl) -3- (((E)-(5- (4- (the chloro- 4- fluoroanilino of 3-) quinazoline -6- base)
Furans -2- base) methylene) hydrazono-) -5- fluoro indole quinoline -2- ketone
F:(E) -1- (2- (diethyllaminoethyl) -3- (((E)-(5- (4- (the chloro- 4- fluoroanilino of 3-) quinazoline -6- base)
Furans -2- base) methylene) hydrazono-) -5--bromo indole quinoline -2- ketone
G:(E) -1- (2- (diethyllaminoethyl) -3- (((E)-(5- (4- (the chloro- 4- of 3- (3- fluorine benzyloxy) phenylamino) quinoline
Oxazoline -6- base) furans -2- base) methylene) hydrazono-) indole-2-ketone
H:(E) -1- (2- (diethyllaminoethyl) -3- (((E)-(5- (4- (the chloro- 4- of 3- (3- fluorine benzyloxy) phenylamino) quinoline
Oxazoline -6- base) furans -2- base) methylene) hydrazono-) -5- fluoro indole quinoline -2- ketone
I:(E) -1- (2- (diethyllaminoethyl) -3- (((E)-(5- (4- (the chloro- 4- of 3- (3- fluorine benzyloxy) phenylamino) quinoline
Oxazoline -6- base) furans -2- base) methylene) hydrazono-) -5--bromo indole quinoline -2- ketone
The synthetic route and synthetic method of above-mentioned Isatine derivatives are as follows:
N- shown in formula 2 is replaced into 4- fragrant amino -6- (5- formylfuran -2- base) quinoline azoles shown in isatin hydrazone and formula 1
Quinoline is condensed in the presence of acetic acid can be obtained Isatine derivatives shown in formula 3.
N- of the present invention replaces the isatin of isatin hydrazone heterozygosis 4- fragrant amino -6- (5- formylfuran -2- base) quinazoline synthesis
The purposes of derivative in the preparation of antitumor drugs, routinely pharmaceutical formulation, with pharmaceutically acceptable carrier according to various
The conventional fabrication process of preparation is made, and can be tablet, granule, capsule etc..
Above-mentioned tumour is people's cutaneous squamous cancer cell A431, human colon cancer cell SW480, Non-small cell lung carcinoma cell
Any one in A549, human lung carcinoma cell NCI-H1975.
The synthetic method of Isatine derivatives of the present invention is simple, has good inhibiting effect to the proliferation of tumour cell, can
Be used to prepare anti-tumor drug, both can medication alone, can also be used in combination with other medicines;Wherein compound A, B, E, G couple
Application on human skin squamous cancer cell A431, human lung carcinoma cell NCI-H1975, human colon cancer cell SW480, Non-small cell lung carcinoma cell
The proliferation of A549 all has apparent inhibiting effect, and effect is substantially better than the anti-tumor drug Lapatinib of clinical use.
Specific embodiment
Below with reference to embodiment, invention is further described in detail, but protection scope of the present invention is not limited only to these
Embodiment.
4- used in following example (3- ethynylanilino) -6- (5- formylfuran -2- base) quinazoline, 4-
(the chloro- 4- fluoroanilino of 3-) -6- (5- formylfuran -2- base) quinazoline bibliography [chemistry notification, 2016,79 (4): 360
~365] the method synthesis in;4- [the chloro- 4- of 3- (3- fluorine benzyloxy) phenylamino] -6- (5- formylfuran -2- base) quinazoline
Bibliography [China Medicine University's journal, 2010,41 (4): the method synthesis in 317~320];1- (diethyllaminoethyl)-
1- hydrogen indoles -2,3- diketone bibliography [Pharmaceutical Chemistry Journal, 2006,40 (11): 595~
602] the method synthesis in;(Z) -1- (diethyllaminoethyl) -3- hydrazone indole-2-ketone referenced patent [US 20120252860]
In method synthesis.Other agents useful for same are that analysis is pure.Compound structure determines nuclear magnetic resonance data used by Bruker
600 NMR spectrometer with superconducting magnet of Avance measurement, using TMS as internal standard;Ir data uses Nicolet 170SX FT-
IR determination of infrared spectroscopy;Fusing point using X-6 micro melting point apparatus (Beijing Tyke Instrument Ltd.) measurement (temperature not into
Row correction);Mass spectrometric data is measured with Bruker Esquire 3000plus mass spectrograph.
Embodiment 1
Synthesize compound A
By 0.1018g (0.3mmol) 4- (3- ethynylanilino) -6- (5- formylfuran -2- base) quinazoline,
0.0780g (0.3mmol) (Z) -1- (diethyllaminoethyl) -3- hydrazone indole-2-ketone, 0.3mL acetic acid, 7mL ethyl alcohol and 0.1mL
N,N-Dimethylformamide is added in reaction flask, and back flow reaction 6 hours at 79 DEG C are cooled to room temperature after having reacted, decompression
Revolving removes solvent, and gained residue is recrystallized with MeOH/THF, obtains red solid i.e. compound A 0.1361g, yield
It is 77.9%, m.p.242.0-244.4 DEG C, structural characterization data are as follows: HRMS (C35H31N7O2)m/z[M+H]+: 582.2614 (meters
Calculation value 582.2617);1H NMR(600MHz,DMSO-d6)δ(ppm):10.16(s,1H),9.05(s,1H),8.74(s,1H),
8.69 (s, 1H), 8.48 (d, J=6.4Hz, 1H), 8.36 (d, J=8.2Hz, 1H), 8.09 (s, 1H), 8.03 (d, J=
7.7Hz, 1H), 7.93 (d, J=8.9Hz, 1H), 7.66-7.65 (m, 1H), 7.54-7.49 (m, 2H), 7.47 (t, J=
7.7Hz, 1H), 7.29 (d, J=7.3Hz, 1H), 7.25 (d, J=7.3Hz, 1H), 7.22-7.17 (m, 1H), 4.26 (s, 1H),
4.12(brs,2H),3.24(brs,4H),1.19(brs,6H);13C NMR(151MHz,DMSO-d6)δ(ppm):164.1,
157.7,157.0,155.0,152.3,151.0,150.0,149.2,146.0,144.4,139.4,133.5,129.6,
129.3,129.0,126.9,126.7,124.9,123.3,123.1,122.6,121.9,119.2,116.7,115.5,
110.6,109.5,83.4,80.7,48.6,46.4,34.8,8.7;IRνmax(KBr)cm-1:3448,2929,1714,1608,
1533,1384,1161,842,746,590。
Embodiment 2
Synthesize compound B
In the present embodiment, is replaced and implemented with equimolar (Z) -1- (diethyllaminoethyl) -3- hydrazone -5- fluoro indole quinoline -2- ketone
(Z) -1- (diethyllaminoethyl) -3- hydrazone indole-2-ketone in example 1, other steps are same as Example 1, obtain red solid
Body, that is, compound B 0.1340g, yield 74.6%, m.p.253.5-256.2 DEG C, structural characterization data are as follows: HRMS
(C35H30FN7O2)m/z[M+H]+: 600.2521 (calculated values 600.2523);1H NMR(600MHz,DMSO-d6)δ(ppm):
10.11 (s, 1H), 9.08 (s, 1H), 8.77 (s, 1H), 8.67 (s, 1H), 8.32 (d, J=8.6Hz, 1H), 8.24 (dd, J=
8.0,2.0Hz, 1H), 8.08 (s, 1H), 7.96 (d, J=8.0Hz, 1H), 7.90 (d, J=8.6Hz, 1H), 7.68 (d, J=
3.5Hz, 1H), 7.50 (d, J=3.5Hz, 1H), 7.45 (t, J=7.9Hz, 1H), 7.41 (td, J=8.7Hz, 2.7Hz, 1H),
7.29-7.28(m,2H),4.21(s,1H),4.14(brs,2H),3.41(brs,2H),3.29-3.22(m,4H),1.22(t,J
=6.7Hz, 6H);13C NMR(151MHz,DMSO-d6)δ(ppm):164.0,159.0,157.8,157.4,157.3,154.1
(d,1JC-F=270Hz), 150.8,149.9,149.1,140.6,139.2,129.1,128.9,128.7,127.1,12 6.7,
125.2,123.7,123.0,121.8,119.6(d,2JC-F=23.4Hz), 119.4,117.3 (d,3JC-F=8.9Hz), 116.4
(d,2JC-F=26.1Hz), 115.5,110.8,110.7 (d,3J C-F=8.2Hz), 83.4,80.6,47.8,46.4,34.7,
8.3;IR νmax(KBr)cm-1:3490,2974,1716,1573,1533,1384,1164,1028,847,574。
Embodiment 3
Synthesize compound C
In the present embodiment, is replaced and implemented with equimolar (Z) -1- (diethyllaminoethyl) -3- hydrazone -5--bromo indole quinoline -2- ketone
(Z) -1- (diethyllaminoethyl) -3- hydrazone indole-2-ketone in example 1, other steps are same as Example 1, obtain red solid
Body, that is, compound C 0.1409g, yield 76.2%, m.p.278.7-281.0 DEG C, structural characterization data are as follows: HRMS
(C35H30ClN7O2)m/z[M+H]+: 616.2218 (calculated values: 616.2228);1H NMR(600MHz,DMSO-d6)δ(ppm):
10.13 (s, 1H), 9.09 (s, 1H), 8.80 (s, 1H), 8.67 (s, 1H), 8.55 (brs, 1H), 8.37 (d, J=8.6Hz,
1H), 8.03 (s, 1H), 7.91 (d, J=8.2Hz, 2H), 7.65 (d, J=3.1Hz, 1H), 7.61 (d, J=7.9Hz, 1H),
7.50 (d, J=3.1Hz, 1H), 7.45 (t, J=8.0Hz, 1H), 7.31-7.27 (m, 2H), 4.23 (s, 1H), 4.14 (brs,
2H),3.40(brs,2H),3.26(brs,4H),1.21-1.20(m,6H);13C NMR(151MHz,DMSO-d6)δ(ppm):
163.7,157.8,157.2,155.0,153.2,150.8,148.9,142.9,139.1,132.6,129.0,128.9,
128.6,127.1,126.6,125.4,124.3,123.1,121.8,119.6,118.0,115.4,111.2,111.1,
110.7,83.3,80.7,47.8,46.4,34.6,8.4;IR νmax(KBr)cm-1:3490,2974,1716,1573,1533,
1384,1164,1028,847,574。
Embodiment 4
Synthesize compound D
In the present embodiment, with equimolar 4- (the chloro- 4- fluoroanilino of 3-) -6- (5- formylfuran -2- base) quinazoline
4- (3- ethynylanilino) -6- (5- formylfuran -2- base) quinazoline in alternative embodiment 1, other steps and implementation
Example 1 is identical, obtains red solid i.e. compound D 0.1526g, yield 83.4%, and m.p.231.5-234.1 DEG C, structure table
Levy data are as follows: HRMS (C33H29ClFN7O2)m/z[M+H]+: 610.2130 (calculated values: 610.2134);1H NMR(600MHz,
DMSO-d6) δ (ppm): 10.21 (s, 1H), 9.01 (s, 1H), 8.74 (s, 1H), 8.68 (s, 1H), 8.47 (d, J=7.4Hz,
1H), 8.36 (d, J=8.4Hz, 1H), 8.20 (d, J=4.8Hz, 1H), 7.93 (d, J=7.8Hz, 2H), 7.65 (d, J=
3.2Hz, 1H), 7.55-7.47 (m, 3H), 7.27 (d, J=7.8Hz, 1H), 7.19 (t, J=7.5Hz, 1H), 4.15 (brs,
2H), 3.42 (brs, 2H), 3.29 (brs, 4H), 1.22 (t, J=6.8Hz, 6H);13C NMR(151MHz,DMSO-d6)δ
(ppm):164.1,157.7,156.9,154.9,154.3,152.7,152.2,150.0(d,1JC-F=263Hz), 149.8,
144.3,136.3(d,4JC-F=1.8Hz), 133.5,129.6,129.4,128.9,126.8 (d,3JC-F=8.8Hz), 123.7,
123.3,123.0,122.5(d,3JC-F=6.8Hz), 119.1,118.9 (d,2JC-F=18.4Hz), 116.7,116.6 (d,2JC-F=21.4Hz), 115.4,110.7,109.6,47.9,46.4,34.5,8.3;IR νmax(KBr)cm-1:3456,2925,
1716,1608,1496,1191,1031,810,752,549。
Embodiment 5
Synthesize compound E
In the present embodiment, is replaced and implemented with equimolar (Z) -1- (diethyllaminoethyl) -3- hydrazone -5- fluoro indole quinoline -2- ketone
(Z) -1- (diethyllaminoethyl) -3- hydrazone indole-2-ketone in example 4, other steps are same as Example 4, obtain red solid
Body, that is, compound E 0.1524g, yield 81.0%, m.p.249.6-252.1 DEG C, structural characterization data are as follows: HRMS
(C33H28ClFN7O2)m/z[M+H]+: 628.2036 (calculated values: 628.2039);1H NMR(600MHz,DMSO-d6)δ(ppm):
10.12 (s, 1H), 8.98 (s, 1H), 8.74 (s, 1H), 8.64 (s, 1H), 8.27 (d, J=7.5Hz, 1H), 8.23 (dd, J=
8.2,2.4Hz, 1H), 8.19 (d, J=4.8Hz, 1H), 7.90 (d, J=7.8Hz, 1H), 7.85 (d, J=8.6Hz, 1H),
7.65 (d, J=3.6Hz, 1H), 7.47-7.44 (m, 2H), 7.40 (td, J=9.0,2.7Hz, 1H), 7.28 (dd, J=8.5,
4.0Hz, 1H), 4.13 (t, J=5.3Hz, 2H), 3.30 (brs, 4H), 1.23 (t, J=7.1Hz, 6H);13C NMR(151MHz,
DMSO-d6)δ(ppm):164.0,158.3(d,1JC-F=215.4Hz), 157.4,157.2,154.8,153.5 (d,1JC-F=
242.2Hz),153.3,150.9(d,4JC-F=2.2Hz), 149.8,149.0,140.5,136.2 (d,4JC-F=2.0Hz),
129.0,128.7,126.7,123.8(d,3JC-F=7.3Hz), 123.7,122.5 (d,3JC-F=6.8Hz), 119.6 (d,2JC-F
=23.4Hz), 119.2,118.8 (d,2JC-F=18.1Hz), 117.3 (d,3JC-F=9.2Hz), 116.5 (d,2JC-F=
21.5Hz),116.4,115.3,110.8,110.6(d,3JC-F=7.4Hz), 48.6,46.4,34.6,8.4;IR νmax(KBr)
cm-1:3431,2979,1720,1614,1498,1166,1029,891,810,547。
Embodiment 6
Synthesize compound F
In the present embodiment, is replaced and implemented with equimolar (Z) -1- (diethyllaminoethyl) -3- hydrazone -5--bromo indole quinoline -2- ketone
(Z) -1- (diethyllaminoethyl) -3- hydrazone indole-2-ketone in example 4, other steps are same as Example 4, obtain red solid
Body, that is, compound F 0.1518g, yield 78.6%, m.p.251.6-252.7 DEG C, structural characterization data are as follows: HRMS
(C33H28Cl2FN7O2)m/z[M+H]+: 644.1731 (calculated values: 644.1744);1H NMR(600MHz,DMSO-d6)δ
(ppm): 10.05 (s, 1H), 8.95 (s, 1H), 8.73 (s, 1H), 8.61 (s, 1H), 8.47 (m, 1H), 8.27 (d, J=
8.7Hz, 1H), 8.13 (d, J=4.5Hz, 1H), 7.84-7.80 (m, 2H), 7.59 (d, J=3.6Hz, 1H), 7.57 (dd, J=
8.5,1.8Hz, 1H), 7.46 (t, J=9.0Hz, 1H), 7.42 (d, J=3.6Hz, 1H), 7.27 (d, J=8.4Hz, 1H),
4.10 (brs, 2H), 3.27 (brs, 4H), 1.21 (t, J=6.9Hz, 6H);13C NMR(151MHz,DMSO-d6)δ(ppm):
163.8,157.6,157.1,154.9,154.3,153.3,152.7,149.8(d,1JC-F=278.3Hz), 148.9,142.8,
136.1 132.5,129.0,128.9,128.6,127.1,126.6,124.2,124.0,122.8(d,3JC-F=6.7Hz),
119.4,118.8(d,2JC-F=18.1Hz), 117.9,116.5 (d,2JC-F=21.6Hz), 115.3,111.1,110.6,
47.8,46.4,34.7,8.8;IRνmax(KBr)cm-1:3525,2935,1722,1608,1496,1365,1031,804,630,
547。
Embodiment 7
Synthesize compound G
In the present embodiment, with equimolar 4- [the chloro- 4- of 3- (3- fluorine benzyloxy) phenylamino] -6- (5- formylfuran -2-
Base) 4- (3- ethynylanilino) -6- (5- formylfuran -2- base) quinazoline in quinazoline alternative embodiment 1, other steps
It is rapid same as Example 1, obtain red solid i.e. compound G 0.1389g, yield 64.7%, m.p.174.5-176.9
DEG C, structural characterization data are as follows: HRMS (C40H35ClFN7O3)m/z[M+H]+: 716.2556 (calculated values: 716.2552);1H NMR
(600MHz,DMSO-d6)δ(ppm):10.23(s,1H),9.26(s,1H),9.06(s,1H),8.74(s,1H),8.65(s,
1H), 8.47 (d, J=7.2Hz, 1H), 8.36 (d, J=8.6Hz, 1H), 8.04 (s, 1H), 7.93 (d, J=8.7Hz, 1H),
7.83 (d, J=8.8Hz, 1H), 7.65 (d, J=2.8Hz, 1H), 7.54-7.45 (m, 3H), 7.31-7.35 (m, 3H), 7.28
(d, J=7.8Hz, 1H), 7.19 (t, J=7.0Hz, 2H), 5.29 (s, 2H), 4.16 (brs, 2H), 3.41 (d, J=4.3Hz,
2H), 3.26-3.27 (m, 4H), 1.22 (t, J=6.8Hz, 6H);13C NMR(151MHz,DMSO-d6)δ(ppm):163.8,
162.2(d,1JC-F=243,1Hz), 157.6,157.0,155.0,152.0,151.0,149.9,149.7,149.1,144.7,
139.6(d,3JC-F=7.6Hz), 133.4,133.1,130.5 (d,3JC-F=9.1Hz), 129.6,129.0,128.7,126.6,
124.4,123.9,123.3(d,4JC-F=1.5Hz), 123.1,122.7,122.1,121.1,119.1,116.5,115.4,
114.6(d,2JC-F=21.1Hz), 114.3,114.0 (d,2JC-F=22.6Hz), 110.5,109.8,109.5,69.4,48.4,
46.5,35.9,9.9;IR νmax(KBr)cm-1:3654,2968,1714,1604,1382,1267,1024,794,750,513。
Embodiment 8
Synthesize compound H
In the present embodiment, is replaced and implemented with equimolar (Z) -1- (diethyllaminoethyl) -3- hydrazone -5- fluoro indole quinoline -2- ketone
(Z) -1- (diethyllaminoethyl) -3- hydrazone indole-2-ketone in example 7, other steps are same as Example 7, obtain red solid
Body, that is, compound H 0.1405g, yield 63.8%, m.p.196.7-197.3 DEG C, structural characterization data are as follows: HRMS
(C40H34ClF2N7O3)m/z[M+H]+: 734.2464 (calculated values: 734.2458);1H NMR(600MHz,DMSO-d6)δ
(ppm): 10.00 (s, 1H), 8.98 (s, 1H), 8.72 (s, 1H), 8.60 (s, 1H), 8.25 (d, J=8.8Hz, 1H), 8.18
(d, J=6.4Hz, 1H), 8.03 (s, 1H), 7.83 (d, J=8.6Hz, 1H), 7.79 (d, J=8.7Hz, 1H), 7.63 (d, J=
2.0Hz, 1H), 7.52-7.46 (m, 1H), 7.44 (d, J=2.6Hz, 1H), 7.37-7.32 (m, 3H), 7.28 (d, J=
9.0Hz,1H),7.22-7.17(m,2H),5.27(s,2H),3.95(brs,2H),2.99(brs,4H),1.06(brs,6H);13C NMR(151MHz,DMSO-d6)δ(ppm):163.7,162.2.(d,1JC-F=244.6Hz), 158.8 (d,1JC-F=
238.6Hz),157.6,157.2(d,3JC-F=6.0Hz), 155.1,153.0,150.9 (d,4JC-F=3.0Hz), 149.9,
149.8,149.0,145.8,141.0,139.6(d,3JC-F=7.5Hz), 132.9,130.5 (d,3JC-F=7.5Hz), 128.8,
128.7,126.5,124.4,124.1,123.5,123.3(d,4JC-F=3.0Hz), 122.6,122.3,121.0,119.5 (d,2JC-F=24.2Hz), 119.2,116.4 (d,2JC-F=25.7Hz), 115.3,114.7 (d,2JC-F=21.1Hz), 114.2,
114.0(d,2JC-F=21.1Hz), 110.6 (d,3JC-F=9.1Hz), 110.6,69.4,48.4,46.5,36.0,10.0;IR
νmax(KBr)cm-1:3332,2636,1710,1617,1498,1417,1269,1028,810,518。
Embodiment 9
Synthesize compound I
In the present embodiment, is replaced and implemented with equimolar (Z) -1- (diethyllaminoethyl) -3- hydrazone -5--bromo indole quinoline -2- ketone
(Z) -1- (diethyllaminoethyl) -3- hydrazone indole-2-ketone in example 7, other steps are same as Example 7, obtain red solid
Body, that is, compound I 0.1379g, yield 61.3%, m.p.199.3-200.9 DEG C, structural characterization data are as follows: HRMS
(C34H21Cl2FN6O3)m/z[M+H]+: 750.2166 (calculated values: 750.2162);1H NMR(600MHz,DMSO-d6)δ
(ppm): 10.16 (s, 1H), 9.03 (s, 1H), 8.77 (d, J=4.6Hz, 1H), 8.62 (s, 1H), 8.52 (d, J=5.4Hz,
1H), 8.33 (t, J=7.7Hz, 1H), 7.97 (s, 1H), 7.85 (t, J=8.3Hz, 1H), 7.73 (d, J=8.3Hz, 1H),
7.68-7.56 (m, 2H), 7.52-7.42 (m, 2H), 7.33 (dd, J=27.2,8.6Hz, 4H), 7.20 (t, J=8.3Hz,
1H), 5.28 (s, 2H), 4.13 (brs, 2H), 3.40 (brs, 2H), 3.28 (brs, 4H), 1.22 (t, J=7.0Hz, 6H);13C
NMR(151MHz,DMSO-d6)δ(ppm):163.8,162.2(d,1JC-F=244.6Hz), 157.9,157.1,154.8,
153.2,150.7,150.1,148.9,142.9,139.6(d,3JC-F=7.5Hz), 132.6,130.5 (d,3JC-F=7.5Hz),
129.0,127.9,127.1,126.7,125.9,124.6,124.3,123.3(d,4JC-F=3Hz), 122.8,122.6,
121.1,119.5,118.0,115.2,114.7(d,2JC-F=21.1Hz), 114.3,114.0 (d,2JC-F=21.1Hz),
111.5,111.2,110.7,69.4,47.8,46.4,34.6,8.3;IR νmax(KBr)cm-1:3422,2640,1714,1598,
1382,1261,1026,981,798,513。
Embodiment 10
Indole-2-ketone derivative of the present invention and its application in preparation of anti-tumor drugs
Inventor using compound A~I of above-described embodiment synthesis as test-compound, tests it to tumour cell respectively
Growth inhibiting effect, specific test situation is as follows:
1, cell strain
Application on human skin squamous cancer cell A431, human lung carcinoma cell NCI-H1975, human colon cancer cell SW480, people's non-small cell
Lung cell A549 is purchased from Shanghai Cell Bank of the Chinese Academy of Sciences.
2, reagent and material
MTT (MPBIO), 96 porocyte culture plates (CorningCostar), fetal calf serum (Gibco), DMEM
(Dulbecco ' s Modified Eagle Medium powder, high glucose, Gibco BRL, Gibco), mould
Element, streptomysin (the green skies), tryptic digestive juice (the green skies), microplate reader (PE Enspire).
3, experimental procedure
(1) cell culture
A431, NCI-H1975, SW480 and A549 cell complete medium (containing 10% (v/v) fetal calf serum,
The DMEM culture medium of 100units/mL penicillin, 100 μ g/mL streptomysins and 2mmol/L L-Glutamine) in, it is placed in saturation
Humidity, 37 DEG C, 5%CO2It is cultivated in incubator.It is primary every passage in 2~3 days.
(2) anti-tumor activity detects
Compound A~I is measured the growth inhibitory activity of tumour cell using mtt assay.Logarithmic growth phase respectively
Human tumor cells, with 0.25% tryptic digestive juice digestion, centrifugation, be resuspended after count, prepare cell suspension, adjustment is thin
Born of the same parents' suspension concentration is 2.0 × 104~5 × 104A/mL.Cell suspension inoculation (100 hole μ L/) in 96 well culture plates is taken, is set full
With humidity, 37 DEG C and 5%CO2It is cultivated for 24 hours in incubator.Test-compound is diluted to required concentration with complete medium, is added
(100 hole μ L/) has been inoculated in 96 well culture plates of human tumor cells, and DMSO final concentration of 0.5% is placed in incubator and cultivates
72h.MTT is added in 96 orifice plates (20 hole μ L/), reacts 4h in incubator.It inhales and abandons liquid in hole, DMSO (150 μ L/ are added
Hole), 10min is shaken on shaking table, and Shi formazan is completely dissolved.Then the absorbance (OD value) at 570nm wavelength is measured with microplate reader,
Absorbance at 630nm wavelength calculates inhibitory rate of cell growth using coordinative solvent as control as reference.
Test-compound is as follows to the calculation of growth of tumour cell inhibiting rate:
Growth of tumour cell inhibiting rate %=[1- (ODs-ODNC)/(ODPC-ODNC)] × 100%
Wherein:
ODSIndicate the absorbance value (cell+untested compound+MTT) of sample well;
ODPCIndicate the absorbance value (cell+DMSO+MTT) of control wells;
ODNCIndicate the absorbance value (complete medium+DMSO+MTT) of zeroing hole;
ODs=OD570s-OD630s;ODPC=OD570PC-OD630PC;ODNC=OD570NC-OD630NC。
Fitting and IC of the test-compound to growth of tumour cell suppression curve50Calculating:
Using Graphpad Prism5 fitting test-compound to the suppression curve of growth of tumour cell, and obtain IC50
Value.3 multiple holes of every group of setting, are at least repeated 3 times.
4, experimental result
Using the anti-tumor drug Lapatinib of clinical use as positive control, experimental result is as shown in table 1.
The IC of 1 test-compound of table inhibition tumor cell proliferation50(μmol/L)
Available by the data in table 1, test-compound A, B, E, G are to application on human skin squamous cancer cell A431, human lung cancer
Cell NCI-H1975, human colon cancer cell SW480, Non-small cell lung carcinoma cell A549 proliferation all have apparent inhibition
Effect, effect are substantially better than Lapatinib;Test-compound C, D are to human colon cancer cell SW480, human lung carcinoma cell NCI-
The proliferation of H1975 and Non-small cell lung carcinoma cell A549 all have apparent inhibiting effect, and effect is better than Lapatinib;By
Examination compound F has apparent inhibiting effect to human colon cancer cell SW480;Test-compound H and I is to application on human skin squamous cancer cell
The proliferation of A431 significantly inhibits.Pharmacological activity statistics indicate that, test-compound A, B, C, D, E, G show compared with
The effect of strong inhibition tumor cell proliferation.
Claims (3)
1. the Isatine derivatives that one kind N- replaces the synthesis of isatin heterozygosis quinazoline compounds, it is characterised in that under the derivative is
Any one in column compound A~I:
A:(E) -1- (2- (diethyllaminoethyl) -3- (((E)-(5- (4- (3- 3-ethynylphenylamino) quinazoline -6- base) furans -2-
Base) methylene) hydrazono-) indole-2-ketone
B:(E) -1- (2- (diethyllaminoethyl) -3- (((E)-(5- (4- (3- 3-ethynylphenylamino) quinazoline -6- base) furans -2-
Base) methylene) hydrazono-) -5- fluoro indole quinoline -2- ketone
C:(E) -1- (2- (diethyllaminoethyl) -3- (((E)-(5- (4- (3- 3-ethynylphenylamino) quinazoline -6- base) furans -2-
Base) methylene) hydrazono-) -5--bromo indole quinoline -2- ketone
D:(E) -1- (2- (diethyllaminoethyl) -3- (((E)-(5- (4- (the chloro- 4- fluoroanilino of 3-) quinazoline -6- base) furan
Mutter -2- base) methylene) hydrazono-) indole-2-ketone
E:(E) -1- (2- (diethyllaminoethyl) -3- (((E)-(5- (4- (the chloro- 4- fluoroanilino of 3-) quinazoline -6- base) furan
Mutter -2- base) methylene) hydrazono-) -5- fluoro indole quinoline -2- ketone
F:(E) -1- (2- (diethyllaminoethyl) -3- (((E)-(5- (4- (the chloro- 4- fluoroanilino of 3-) quinazoline -6- base) furan
Mutter -2- base) methylene) hydrazono-) -5--bromo indole quinoline -2- ketone
G:(E) -1- (2- (diethyllaminoethyl) -3- (((E)-(5- (4- (the chloro- 4- of 3- (3- fluorine benzyloxy) phenylamino) quinoline azoles
Quinoline -6- base) furans -2- base) methylene) hydrazono-) indole-2-ketone
H:(E) -1- (2- (diethyllaminoethyl) -3- (((E)-(5- (4- (the chloro- 4- of 3- (3- fluorine benzyloxy) phenylamino) quinoline azoles
Quinoline -6- base) furans -2- base) methylene) hydrazono-) -5- fluoro indole quinoline -2- ketone
I:(E) -1- (2- (diethyllaminoethyl) -3- (((E)-(5- (4- (the chloro- 4- of 3- (3- fluorine benzyloxy) phenylamino) quinoline azoles
Quinoline -6- base) furans -2- base) methylene) hydrazono-) -5--bromo indole quinoline -2- ketone
2. N- described in claim 1 replace the Isatine derivatives of isatin heterozygosis quinazoline compounds synthesis prepare it is antitumor
Purposes in drug.
3. N- according to claim 2 replaces the purposes of Isatine derivatives in the preparation of antitumor drugs, it is characterised in that:
The tumour is people's cutaneous squamous cancer cell A431, human colon cancer cell SW480, Non-small cell lung carcinoma cell A549, people
Any one in lung carcinoma cell NCI-H1975.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711118862.4A CN107903248B (en) | 2017-11-14 | 2017-11-14 | N- replaces the Isatine derivatives and application in preparation of anti-tumor drugs of isatin heterozygosis quinazoline compounds synthesis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711118862.4A CN107903248B (en) | 2017-11-14 | 2017-11-14 | N- replaces the Isatine derivatives and application in preparation of anti-tumor drugs of isatin heterozygosis quinazoline compounds synthesis |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107903248A CN107903248A (en) | 2018-04-13 |
CN107903248B true CN107903248B (en) | 2019-04-09 |
Family
ID=61844025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711118862.4A Active CN107903248B (en) | 2017-11-14 | 2017-11-14 | N- replaces the Isatine derivatives and application in preparation of anti-tumor drugs of isatin heterozygosis quinazoline compounds synthesis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107903248B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113480559B (en) * | 2021-07-13 | 2022-06-03 | 北京大学深圳医院 | Artemether derivative and preparation method and application thereof |
CN116621767B (en) * | 2023-02-23 | 2024-05-31 | 中山大学 | Isatin derivative and preparation method and application thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120190009A1 (en) * | 2010-12-14 | 2012-07-26 | Fatah Kashanchi | Viral Modulators and Processes Thereof |
CN103058938A (en) * | 2011-10-18 | 2013-04-24 | 南京大学 | 4-aniline quinazoline compound substituting cinnamic acid, and preparation method and application thereof |
US9394303B2 (en) * | 2014-04-04 | 2016-07-19 | The Regents Of The University Of Michigan | Small molecule inhibitors of MCL-1 and uses thereof |
-
2017
- 2017-11-14 CN CN201711118862.4A patent/CN107903248B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN107903248A (en) | 2018-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10774070B2 (en) | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors | |
TWI675840B (en) | Fused pyrimidine compound or salt thereof | |
KR101839915B1 (en) | Arylamino purine derivatives, preparation method and pharmaceutical use thereof | |
Shi et al. | Discovery of quinazolin-4-amines bearing benzimidazole fragments as dual inhibitors of c-Met and VEGFR-2 | |
JP7320823B2 (en) | Use of pteridinone derivatives as EGFR inhibitors | |
CN108658962B (en) | 3-substituted coumarin furazan derivative and application thereof in preparation of multidrug-resistant tumor drugs | |
CN105985342A (en) | Pyrimido pyrimidine dione derivative as EGFR inhibitor and application thereof | |
CN107903248B (en) | N- replaces the Isatine derivatives and application in preparation of anti-tumor drugs of isatin heterozygosis quinazoline compounds synthesis | |
CN113307797A (en) | Polysubstituted quinazoline compound and application thereof | |
CN107129506B (en) | As pyrimido [4,5-d] [1,3] oxazines -2- ketone derivatives of EGFR inhibitor and its application | |
CN104250252B (en) | Pyrazolo [1,5 a] pyrimidines and preparation method thereof and medical usage | |
AboulMagd et al. | Saccharomonosporine A inspiration; synthesis of potent analogues as potential PIM kinase inhibitors | |
CN103382182B (en) | Phenylurea coupling quinazoline compounds and preparation method thereof, pharmaceutical composition and medicinal usage | |
Elattar et al. | Insights into the recent progress in the medicinal chemistry of pyranopyrimidine analogs | |
CN113501819B (en) | Pyridoimidazole substituted quinazolinone derivative, and synthetic method and application thereof | |
CN107383019B (en) | Pyrazolo [4,3-h] quinazoline compounds and application thereof | |
CN105017162B (en) | 4 pairs of propenylbenzene amido quinazoline derivatives and its application in antineoplastic is prepared | |
CN106892922B (en) | As the 5,8- dihydropteridine -6,7- derovatives of EGFR inhibitor and its application | |
CN109516959A (en) | 2- fragrant amino -4- substituted uracil derivative and its application in preparation of anti-tumor drugs | |
CN106632287B (en) | The Isatine derivatives and its application in preparation of anti-tumor drugs of isatin heterozygosis quinazoline compounds synthesis | |
CN107827877B (en) | Dialkylamino quinazoline compound and application thereof in preparation of antitumor drugs | |
CN113461661B (en) | 6- (pyridin-3-yl) quinazoline-4 (3H) -ketone derivative and preparation and application thereof | |
CN102942561A (en) | 4-amino quinazoline heterocyclic compound and purpose of 4-amino quinazoline heterocyclic compound | |
Mule et al. | Synthesis, biological screening and molecular docking studies of novel 4, 6-pyrimidine derivatives as EGFR-TK inhibitors | |
Ying et al. | Design, synthesis and biological characteristics of pyrazolo [3, 4-d] pyrimidine derivatives as potential VEGFR-2 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |